Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Resource Type
Article
Authors
Wu, Yi-Long ; Liu, Xiaoqing ; Liu, Zhe ; Lu, Shun ; Chen, Xi ; Pan, Hongming ; Wang, Mengzhao ; Yu, Shiying ; Zhang, Helong ; Zhang, Yiping ; Fang, Jian ; Li, Wei ; Zhou, Jianying ; Zhao, Jun ; Cheng, Ying ; Yang, Chih-Hsin ; Chang, Gee-Chen ; Chen, Yuh-Min ; Hsia, Te-Chun ; Chian, Chih-Feng ; Yang, Cheng-Ta ; Wang, Chin-Chou ; Kim, Sang-We ; Park, Keunchil ; Kim, Dong-Wan ; Cho, Byoung Chul ; Lee, Ki Hyeong ; Kim, Young-Chul ; An, Ho Jung ; Woo, In Sook ; Cho, Jae Yong ; Shin, Sang Won ; Lee, Jong-Seok ; Kim, Joo-Hang ; Yoo, Seung Soo ; Kato, Terufumi ; Shinagawa, Naofumi ; Soo, Ross Andrew ; Tan, Shao Weng Daniel ; Ngo, Lynette Si-Mien ; Ratnavelu, Kananathan ; Ahmad, Azura Rozila ; Liam, Chong Kin ; de Marinis, Filippo ; Tassone, Pierfrancesco ; Molla, Amelia Insa ; Calles Blanco, Antonio ; Lazaro Quintela, Martin Emilio ; Felip Font, Enriqueta ; Dingemans, Anne-Marie ; Bui, Lynne ; Tan, Daniel Shao Weng ; Bruns, Rolf ; Straub, Josef ; Johne, Andreas ; Scheele, Jürgen ; Yang, James Chih-Hsin
Source
In The Lancet Respiratory Medicine November 2020 8(11):1132-1143
Subject
Primary Research Articles
Language
ISSN
2213-2600